Should we be trying to increase butyrate in the gut?

Sasha

Senior Member (Voting Rights)
I've just been reading The Anti-Viral Gut by gastroenterologist Robynne Chutkan, which focuses quite a bit on Covid. In it, she says that in a large study of Covid patients, the composition of the gut microbiome predicted the development of severe respiratory symptoms and death with 92% accuracy; and that Covid disease severity is inversely related with the levels of Faecalibacterium prausnitzii (a butyrate-producer) in the gut.

She says that short-chain fatty acids (SCFAs) help orchestrate immune equilibrium (preventing an overblown response to infection) and help tighten up the gut epithelial barrier, which stops virus leaking through it; and that the more F. prausnitzii you have in your gut, the less susceptible to viral illness you will be.

The Guo et al. 2023 study, 'Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS' (other authors included Lipkin, Hornig, Vernon, Bateman, Montoya and other big ME/CFS names) found:

NIH study said:
Faecalibacterium prausnitzii and Eubacterium rectale, which are both recognized as abundant, health-promoting butyrate producers in the human gut, were reduced in ME/CFS. Functional metagenomics, qPCR, and metabolomics of fecal short-chain fatty acids confirmed a deficient microbial capacity for butyrate synthesis. [...] The abundance of Faecalibacterium prausnitzii was inversely associated with fatigue severity. These findings demonstrate the functional nature of gut dysbiosis and the underlying microbial network disturbance in ME/CFS, providing possible targets for disease classification and therapeutic trials.

In this webinar, Lipkin discusses these results and says:

Lipkin said:
One of the things that I would be most excited to try to address would be to identify those individuals who have very low levels of butyrate-producing bacteria, and find out whether by using prebiotics and probiotics which are really fairly benign, whether or not we can show some sort of an improvement in symptoms.

Dr Chutkan says you can boost your levels of F. prausnitzii by eating a salad every day (she didn't say why - maybe for the bugs they carry) and eating foods rich in the prebiotic inulin (onions, garlic, leeks, asparagus, etc.). (You can also buy inulin powder, but she doesn't mention that.)

I'm conscious that Ken Lassensen has famously managed to put himself into remission several times with a gut approach. He puts a lot of information out there and says that other people have reported improvements from his approach but I found his website overwhelming at a first glance and don't know what he does.

Anyway, what do we think? Should be trying to increase our F. prausnitzii and butyrate? Is a trial under way? If one isn't, should we be pushing for one?
 
Is butyrate a thing that ever makes people worse?
This is ME we're talking about, so pretty much anything has potential to make ME worse. Strengthening the intestinal barrier might reduce some signal that was keeping some other mechanism under control, resulting in worsening. With ME, I expect that most treatments that provide some benefit for some people will also make at least a few other people worse. If you did a butyrate supplement study with 1000 PWME, I would be really surprised if none of them reported worsening. There are just too many complex interactions involved.

The question is whether butyrate supplementation is worth the expense of a proper trial. I expect there are plenty of PWME who have followed butyrate-producing diets or consumed lots of butter (I don't know whether that butyrate reaches far down the digestive tract). If hundreds of those people reported major improvements from butyrate-boosting, then it might be worth a proper trial. Without that observational evidence, it's just another theory for a treatment that might provide a benefit.
 
The question is whether butyrate supplementation is worth the expense of a proper trial. I expect there are plenty of PWME who have followed butyrate-producing diets or consumed lots of butter (I don't know whether that butyrate reaches far down the digestive tract). If hundreds of those people reported major improvements from butyrate-boosting, then it might be worth a proper trial. Without that observational evidence, it's just another theory for a treatment that might provide a benefit.

I don't know that people realise when they're following a butyrate-producing diet, so I think it would be hard to get that kind of observational evidence. I doubt that most people know what butyrate is.
 
Is butyrate a thing that ever makes people worse? (Honest question! I've only ever seen it mentioned as something benign.)

I googled 'butyrate diet'. The second hit was a study in mice finding that a high butyrate diet made them more susceptible to e coli, and the third was the Cleveland Clinic saying high butyrate levels can cause bloating in those with a 'sensitive gut'.
 
There is a NIH funded trial for Gulf War illness that will test this:

Microbiome targeted oral butyrate therapy in Gulf War multisymptom illness
The goal of this clinical trial is to determine if a Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives in a single oral capsule administered twice a day is effective in increasing physical functioning for Veterans with Gulf War Illness. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome (that have been found altered in GWI veterans), (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain) (c) decreasing chronic fatigue, (d) decreasing systemic inflammation such a blood levels of proinflammatory cytokines and (d) a decrease in cognitive deficits. The clinical trial involving butyrate on Gulf War Illness veterans will be conducted in three sites across the nation.
https://reporter.nih.gov/search/dw8kmGn1VkulvUJ3tkikaQ/project-details/10784587
 
@Neuroscope_mp on Twitter is fascinated by Faecalibacterium prausnitzii as well:
A gut bacterium is showing up — or rather disappearing — across all three phases of COVID-19.

Severely ill patients have less of it.
Recovered patients get it back.
Long COVID patients don't.

Its name is Faecalibacterium prausnitzii. And what it does explains a lot.

Video thumbnail


HD


F. prausnitzii is one of the most abundant bacteria in a healthy human gut.

It produces butyrate — a molecule that:

• Fuels your colon lining
• Seals your gut barrier
• Suppresses inflammatory signals
• Regulates your immune system

When it disappears, all of that fails at once.

Tweet image 1


Severe COVID-19

A 2025 meta-analysis pooling data across 10 independent studies confirmed:

F. prausnitzii depletion: logFC = -1.24 (95% CI -1.68 to -0.80)

Translation: It was significantly lower in every severe COVID cohort analyzed.

The more depleted. The sicker the patient.

Video thumbnail


HD


Recovery

Patients who fully recovered from COVID-19 showed normalization of their gut microbiome — including return of F. prausnitzii — within approximately 6 months.

Butyrate-producing bacteria were among the first to come back.

The gut was healing. The bacteria were the signal.

Tweet image 1


Long COVID

Liu et al. 2022 (Gut journal) tracked 106 Long COVID patients over 6 months.

F. prausnitzii and Bifidobacterium pseudocatenulatum showed the STRONGEST inverse correlation with Long COVID development of any bacteria studied.

Less of them at baseline = more likely to have persistent symptoms.

Tweet image 1


Why does this matter beyond the gut?

↓ F. prausnitzii → ↓ butyrate → gut barrier breaks down
→ inflammatory signals enter bloodstream
→ cross into the brain
→ microglial activation
→ brain fog, memory problems, fatigue

This is the same gut-brain pathway seen in Parkinson's and Alzheimer's disease.

Long COVID may be hijacking the same route.

Tweet image 1


A randomized controlled trial just tested this.

463 Long COVID patients. Synbiotic targeting gut bacteria (SIM01) vs placebo. 6 months.

Results (Lancet Infectious Diseases 2024):

Difficulty concentrating: 62% vs 39% alleviated ✓
Memory loss: 42% vs 27% ✓
Fatigue: 63% vs 43% ✓

Pulmonary symptoms: no significant difference.

The gut fixed the brain symptoms. Not the lungs. That tells us something.

Tweet image 1


What we do NOT yet know:

• Whether F. prausnitzii depletion causes Long COVID — or is caused by it — or both
• The SIM01 trial used vitamin C as placebo, not inert starch
• Results need independent replication
• Direct F. prausnitzii supplement does not exist yet

Association is strong. Causation is unproven. That's where the science actually is.

Tweet image 1


No F. prausnitzii supplement exists yet. But you can feed it.

It thrives on fermentable fibre:

✓ Jerusalem artichoke
✓ Chicory root
✓ Leeks, asparagus, onion
✓ Resistant starch (underripe banana, cooled rice)
✓ Mediterranean diet pattern overall

NOTE: Probiotics carry real risks for immunocompromised individuals and the elderly. Always consult your doctor.

Tweet image 1


This is part of a disease series on Faecalibacterium prausnitzii — one gut bacterium found depleted across Parkinson's, Alzheimer's, MS, IBD, diabetes, cancer, and now Long COVID.

They also mention two papers that weren’t on S4ME yet:
Gut Microbiome Composition and Dynamics in Hospitalized COVID-19 Patients and Patients with Post-Acute COVID-19 Syndrome

Brīvība, Monta; Silamiķele, Laila; Birzniece, Līga; Ansone, Laura; Megnis, Kaspars; Silamiķelis, Ivars; Pelcmane, Līva; Borisova, Daniella; Rozenberga, Maija; Jagare, Lauma; Elbere, Ilze; Kloviņš, Jānis

Abstract
The gut microbiome plays a pivotal role in the modulation of host responses during viral infections, and recent studies have underscored its significance in the context of coronavirus disease 2019 (COVID-19). We aimed to investigate the dynamics and compositional changes in the gut microbiome of COVID-19 patients, addressing both the acute phase and the recovery process, with a particular focus on the emergence of post-COVID-19 conditions. Involving 146 COVID-19 patients and 110 healthy controls, this study employed a shotgun metagenomics approach for cross-sectional and longitudinal analyses with one- and three-month follow-ups. We observed a decline in taxonomic diversity among hospitalized COVID-19 patients compared to healthy controls, while a subsequent increase in alpha diversity was shown during the recovery process. A notable contribution of Enterococcus faecium was identified in the acute phase of the infection, accompanied by an increasing abundance of butyrate-producing bacteria (e.g., Roseburia, Lachnospiraceae_unclassified) during the recovery period. We highlighted a protective role of the Prevotella genus in the long-term recovery process and suggested a potential significance of population-specificity in the early gut microbiome markers of post-acute COVID-19 syndrome. Our study represents distinctive gut microbiome signatures in COVID-19, with potential diagnostic and prognostic implications, pinpointing potential modulators of the disease progression.

Web | DOI | PMC | PDF | International Journal of Molecular Sciences
Gut Microbiome Dysbiosis in COVID-19: A Systematic Review and Meta-Analysis of Diversity Indices, Taxa Alterations, and Mortality Risk

Mateescu, Diana-Maria; Ilie, Adrian-Cosmin; Cotet, Ioana; Guse, Cristina; Muresan, Camelia-Oana; Pah, Ana-Maria; Badalica-Petrescu, Marius; Iurciuc, Stela; Craciun, Maria-Laura; Avram, Adina; Margan, Madalin-Marius; Enache, Alexandra

Abstract
COVID-19 is associated with gut microbiome alterations that may influence disease outcomes through immune and inflammatory pathways. This systematic review and meta-analysis evaluated global evidence on gut dysbiosis in COVID-19. We searched PubMed/MEDLINE, Embase, Web of Science, Scopus, and Cochrane Library up to 5 October 2025 (PROSPERO CRD420251160970). Alpha-diversity indices and microbial taxa log-fold changes (logFC) were analyzed using random-effects models. The pooled standardized mean difference (SMD) for the Shannon index was −0.69 (95% CI −0.84 to −0.54; I2 = 42%), confirming reduced microbial diversity. Faecalibacterium prausnitzii showed a significant pooled depletion (logFC = −1.24; 95% CI −1.68 to −0.80; k = 10; I2 = 74%), while Enterococcus spp. was increased (logFC = 1.45; 95% CI 1.12–1.78). Egger’s test did not suggest publication bias (p = 0.32). Gut dysbiosis was consistently associated with reduced microbial diversity and enrichment of pathogenic taxa, correlating with increased disease severity and mortality (HR = 1.67). These findings highlight the potential of microbiome profiling as a prognostic tool in COVID-19, although clinical translation requires further validation.

Web | DOI | PMC | PDF | Microorganisms
 
Back
Top Bottom